To further demonstrate the therapeutic efficacy of W2014-S, subcutaneous mouse xenografts of NSCLC cell line (A549) and lung cancer patient-derived xenograft (PDX) model harboring aberrantly active STAT3 were utilized to evaluate the anti-tumor effect. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.